Stock Financial Ratios, Dividends, Split History

CTIC / CTI BioPharma Corp. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)239.44
Enterprise Value ($M)143.21
Book Value ($M)82.78
Book Value / Share1.43
Price / Book2.89
NCAV ($M)69.08
NCAV / Share1.19
Price / NCAV3.47
Share Statistics
Common Shares Outstanding 57,982,860
Common Stock Shares Outstanding 42,969,494
Scoring Models
Piotroski F-Score2.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-1.14
Return on Assets (ROA)-0.64
Return on Equity (ROE)-3.07
Balance Sheet (mrq) ($M)
Quick Ratio5.30
Current Ratio5.32
Income Statement (mra) ($M)
Licenses Revenue0.00
License And Services Revenue24,293,000.00
Sales Revenue Goods Net853,000.00
Operating Income-39.52
Net Income-40.83
Earnings Per Share Basic And Diluted-1.24
Earnings Per Share Diluted-1.24
Earnings Per Share Basic-1.24
Cash Flow Statement (mra) ($M)
Cash From Operations-39.30
Cash from Investing-0.04
Cash from Financing-0.04
Identifiers and Descriptors
Central Index Key (CIK)891293
Related CUSIPS
12648L956 12648L901 12648L906 12648L601

Split History

Stock splits are used by CTI BioPharma Corp. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

22h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

23h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

Pharma Stock Roundup: PFE to Split Into 3 Units, J&J to Pay $4.7B in Talc Lawsuit

2018-07-13 zacks
The biggest news this week was Pfizer’s (PFE - Free Report) announcement of its plans to re-organize its business into three new segments, effective next year. J&J (JNJ - Free Report) was ordered by a St Louis jury to pay approximately $4.7 billion to nearly two dozen women in a lawsuit related to its talc-based products. Merck (MRK - Free Report) , AbbVie (ABBV - Free Report) and Bristol-Myers (BMY - Free Report) provided updates on their cancer drugs. (14-0)

Your Daily Pharma Scoop: IsoRay Doubles, OncoCyte Zooms, Celgene Sluggish

2018-07-11 seekingalpha
Note: ISR has a market cap of less than $100mn and trades below $1. These stocks are inherently risky, and we do not invest in such stocks. However, on Monday, on this news, the stock went above $1, which is when we covered it. (53-3)

CTI BioPharma Falls After Failure of Pivotal Lymphoma Study

2018-07-10 zacks
CTI BioPharma Corp. (CTIC - Free Report) and its privately-held partner Servier announced the failure of their pivotal phase III study evaluating cancer drug, Pixuvri, in combination with Roche (RHHBY - Free Report) and Biogen’s (BIIB - Free Report) Rituxan (rituximab) for the treatment of B-cell non-Hodgkin lymphoma (“NHL”). (5-0)

CTI Shares Plunge After NHL Treatment Fails in Phase III Trial

2018-07-09 biospace
Shares of Seattle-based CTI BioPharma Corp. are down more than 15 percent in premarket trading this morning after the company announced its combination treatment for B-cell non-Hodgkin lymphoma failed to meet endpoints in a late-stage trial. (1-0)

UPDATE 1-CTI Biopharma's cancer drug fails late-stage trial

2018-07-09 reuters
(Reuters) - CTI Biopharma Corp said on Monday its treatment for a type of blood cancer did not meet the main goal of a late-stage trial. (1-0)

CUSIP: 12648L106